JAGXJaguar Health, Inc.

Nasdaq jaguar.health


$ 0.28 $ -0.02 (-5.3 %)    

Tuesday, 14-May-2024 15:56:13 EDT
QQQ $ 445.88 $ 2.85 (0.64 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 2.39 (0.46 %)
TLT $ 90.86 $ 0.51 (0.56 %)
GLD $ 218.12 $ 1.83 (0.85 %)
$ 0.2749
$ 0.28
$ 0.28 x 100
$ 0.00 x 0
$ 0.27 - $ 0.33
$ 0.05 - $ 0.94
63,969,137
na
43.67M
$ 1.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-24-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-22-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-17-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 04-03-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-21-2019 03-31-2019 10-Q
22 04-10-2019 12-31-2018 10-K
23 11-19-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-09-2018 12-31-2017 10-K
27 11-20-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 02-15-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-29-2016 12-31-2015 10-K
35 11-13-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 06-26-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jaguar-health-announces-submission-of-clinical-trial-applications-for-crofelemer-to-treat-rare-disease-indications-microvillus-inclusion-disease-and-short-bowel-syndrome-in-europe

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the Europea...

 fda-conditionally-approves-jaguar-healths-prescription-drug-crofelemer-for-chemotherapy-induced-diarrhea-in-dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the v...

 jaguar-health-inc-files-for-mixed-shelf-offering-of-up-to-75m

 - SEC Filing

 sp-500-edges-lower-pacbio-shares-plunge

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.0...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 gold-moves-higher-morgan-stanley-earnings-top-views

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded up 0...

 why-jaguar-health-stock-is-up-today

Jaguar Health shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreem...

 jaguar-health-licenses-fda-approved-oral-mucositis-product-for-us-market-initiating-commercial-footprint-in-its-core-focus-area-of-cancer-supportive-care-planning-to-begin-commercial-launch-in-q3-2024-for-gelclair

Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription productOral mucositis...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION